What is the best approach for managing multiple sclerosis (MS) in a war zone where immunotherapy is not available?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Multiple Sclerosis in War Zone Settings Without Immunotherapy

In a war zone where immunotherapy is unavailable, high-dose oral corticosteroids (methylprednisolone) combined with cyclophosphamide should be the primary treatment approach for managing multiple sclerosis, with symptomatic management and rehabilitation as essential complementary strategies.

Assessment and Prioritization in War Zone Settings

When managing MS in a war zone without access to standard immunotherapies, focus on:

  • Determining disease pattern (relapsing-remitting vs. progressive forms)
  • Assessing current disability level using simplified neurological examination
  • Identifying acute relapses requiring immediate intervention
  • Evaluating comorbidities that may complicate treatment

First-Line Treatment Options

For Acute Relapses

  • High-dose methylprednisolone: 160mg daily for 5-7 days, followed by oral prednisone taper 1
    • Can be administered IV if available or orally if IV access is limited
    • No need for gradual tapering if treatment duration is less than 7-10 days
    • Monitor for infection risk, which is heightened in war zone conditions

For Disease Modification

  • Cyclophosphamide: Consider as primary disease-modifying agent when immunotherapies are unavailable 2
    • Dosing: Weekly cyclophosphamide (oral preferred in war zone) with dexamethasone
    • Particularly effective for intermediate-risk MS patients
    • Requires monitoring for myelosuppression but less intensive than melphalan-based regimens

Symptomatic Management

Symptomatic treatment becomes crucial when disease-modifying therapies are unavailable:

  • Spasticity: Baclofen (oral) starting at 5mg TID, gradually increasing as needed
  • Neuropathic pain: Gabapentin, carbamazepine, or amitriptyline (based on availability)
  • Fatigue: Amantadine if available; otherwise, energy conservation strategies
  • Bladder dysfunction: Anticholinergics if available; intermittent catheterization if necessary
  • Depression: SSRIs if available; supportive counseling regardless

Practical Considerations for War Zone Settings

  • Medication stockpiling: Prioritize oral medications with longer shelf-life
  • Rehabilitation: Implement simple physical therapy exercises that can be performed without specialized equipment
  • Infection prevention: Critical due to increased infection risk from both MS treatments and war zone conditions 2
  • Documentation: Maintain simplified records of treatments and responses to facilitate continuity of care

Special Considerations

Progressive MS Forms

For progressive forms of MS in a war zone, focus on:

  • Cyclophosphamide-based regimens which may slow disability progression 2
  • Intensive symptomatic management to maintain function
  • Rehabilitation strategies that can be implemented with minimal resources

Infection Risk Management

  • Prophylactic antibiotics should be considered for patients on cyclophosphamide
  • Avoid live vaccines; ensure patients have received inactivated vaccines before treatment if possible 3
  • Monitor for opportunistic infections, particularly respiratory infections 2

Long-term Planning

  • Establish clear criteria for treatment success or failure
  • Develop contingency plans for treatment interruptions
  • Create protocols for evacuation priorities if medical evacuation becomes possible
  • Plan for transition to standard immunotherapies when they become available again

Pitfalls to Avoid

  • Don't delay treatment of acute relapses waiting for optimal conditions
  • Don't overlook infection risk in patients on immunosuppressive therapy in unsanitary conditions
  • Don't neglect symptomatic management which can significantly improve quality of life even when disease-modifying options are limited
  • Don't use melphalan as first-line therapy due to increased leukemogenicity and myelosuppression risks 2

While this approach is not optimal compared to modern immunotherapies, it represents the best evidence-based strategy for managing MS in resource-limited war zone settings where standard immunotherapies are unavailable.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Multiple Sclerosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.